S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
S&P 500   4,592.59 (+0.56%)
DOW   34,567.82 (+0.24%)
QQQ   395.81 (+0.51%)
AAPL   169.17 (+2.34%)
MSFT   335.59 (+1.51%)
FB   317.65 (-2.10%)
GOOGL   2,877.31 (+1.39%)
AMZN   3,505.48 (-0.05%)
TSLA   1,141.57 (-0.28%)
NVDA   323.06 (-1.13%)
BABA   125.05 (-1.94%)
NIO   39.70 (+1.46%)
CGC   10.35 (-3.36%)
AMD   154.34 (-2.54%)
GE   95.35 (+0.38%)
MU   87.56 (+4.24%)
T   22.51 (-1.40%)
F   20.08 (+4.64%)
DIS   144.90 (+0.00%)
PFE   54.34 (+1.14%)
ACB   6.23 (-2.96%)
AMC   32.16 (-5.24%)
BA   194.16 (-1.87%)
NASDAQ:BXRX

Baudax Bio Stock Forecast, Price & News

$0.37
-0.01 (-1.75%)
(As of 12/1/2021 01:01 PM ET)
Add
Compare
Today's Range
$0.37
$0.38
50-Day Range
$0.38
$0.61
52-Week Range
$0.36
$2.12
Volume
14,700 shs
Average Volume
3.25 million shs
Market Capitalization
$31.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.09
30 days | 90 days | 365 days | Advanced Chart
Receive BXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.


Baudax Bio logo

About Baudax Bio

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Headlines

Pre-market Movers: BXRX, CARA, HGBL, REKR, TBPH…
August 24, 2021 |  markets.businessinsider.com
Baudax Bio: Q2 Earnings Insights
August 5, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BXRX
Employees
57
Year Founded
N/A

Sales & Book Value

Annual Sales
$490 thousand
Book Value
($0.30) per share

Profitability

Net Income
$-76.10 million
Net Margins
-8,762.57%
Pretax Margin
-8,762.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
82,229,000
Market Cap
$31.24 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/15/2022

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

1128th out of 1,392 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

18th out of 22 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Baudax Bio (NASDAQ:BXRX) Frequently Asked Questions

How has Baudax Bio's stock been impacted by COVID-19 (Coronavirus)?

Baudax Bio's stock was trading at $4.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BXRX stock has decreased by 92.5% and is now trading at $0.37.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Baudax Bio?

Baudax Bio saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 2,940,000 shares, an increase of 16.7% from the October 14th total of 2,520,000 shares. Based on an average daily trading volume, of 3,110,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 3.6% of the company's stock are short sold.
View Baudax Bio's Short Interest
.

When is Baudax Bio's next earnings date?

Baudax Bio is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Baudax Bio
.

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) posted its earnings results on Thursday, November, 4th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.04. During the same period in the previous year, the business earned ($0.72) earnings per share.
View Baudax Bio's earnings history
.

Who are Baudax Bio's key executives?

Baudax Bio's management team includes the following people:

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

What is Baudax Bio's stock symbol?

Baudax Bio trades on the NASDAQ under the ticker symbol "BXRX."

Who are Baudax Bio's major shareholders?

Baudax Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.58%), Geode Capital Management LLC (0.81%), Millennium Management LLC (0.39%), UBS Group AG (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Baudax Bio stock include Arnold M Baskies, Geraldine Henwood, Richard S Casten, Wayne Weisman and Winston J Churchill.
View institutional ownership trends for Baudax Bio
.

Which institutional investors are buying Baudax Bio stock?

BXRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Geode Capital Management LLC, UBS Group AG, and BlackRock Inc.. Company insiders that have bought Baudax Bio stock in the last two years include Arnold M Baskies, Geraldine Henwood, Richard S Casten, Wayne Weisman, and Winston J Churchill.
View insider buying and selling activity for Baudax Bio
or or view top insider-buying stocks.

How do I buy shares of Baudax Bio?

Shares of BXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Baudax Bio's stock price today?

One share of BXRX stock can currently be purchased for approximately $0.37.

How much money does Baudax Bio make?

Baudax Bio has a market capitalization of $31.24 million and generates $490 thousand in revenue each year.

How many employees does Baudax Bio have?

Baudax Bio employs 57 workers across the globe.

What is Baudax Bio's official website?

The official website for Baudax Bio is www.baudaxbio.com.

Where are Baudax Bio's headquarters?

Baudax Bio is headquartered at 490 LAPP ROAD, MALVERN PA, 19355.

How can I contact Baudax Bio?

Baudax Bio's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The company can be reached via phone at 484-395-2440, via email at [email protected], or via fax at 484-395-2471.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.